Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

HCRN-GU16-257

Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing

Status: Closed to Accrual

Learn more:

Manuscripts/Articles: 

  • M Galsky, S Daneshmand, S Izadmehr, E Gonzalez-Kozlova, K Chan, S Lewis, B El Achkar, T Dorff, J Paul Cetnar, B Neil, A D’Souza, R Mamtani, C Kyriakopoulos, T Jun, M Gogerly-Moragoda, R Brody, H Xie, K Nie, G Kelly, A Horwitz, Y Kinoshita, E Ellis, Y Nose, G Ioannou, R Cabal, G Kenneth Haines, L Wang, K Mouw, R Samstein, R Mehrazin, N Bhardwaj, M Yu, Q Zhao, S Kim-Schulze, R Sebra, J Zhu, S Gnjatic, J Sfakianos, S K. Pal. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial HCRN-GU16-257. DOI: 10.1038/s41591-023-02568-1 Nature Communications. 2023 October 2. See Abstract. 

Abstracts/Posters/Presentations:

  • MD Galsky, S Daneshmand, KG Chan, TB Dorff, JP Cetnar, B O’Neil, A D’souza, R Mamtani, C Kyriakopoulos, P Garcia, S Izadmehr, M Yu, Q Zhao, R Mehrazin, SC Lewis, J Sfakianos, SK Pal. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU16-257. Presented as an oral abstract at the ASCO 2021 Annual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 4503) See abstract. See related coverage at cancernetwork.com.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.